Literature DB >> 31149189

LOW O6-METHYLGUANINE-DNA METHYTRANSFERASE (MGMT) AND PAN-CYTOKERATIN (PAN-CK) EXPRESSION VIA IMMUNOHISTOCHEMISTRY IN PITUITARY ADENOMAS.

R Basaran1, M Onoz2, F H Bolukbasi2, M Efendioglu1, A Sav3.   

Abstract

INTRODUCTION: Pituitary adenomas (PA) are the third most common intracranial tumors, with an incidence rate of 10-15%. More than half are invasive, infiltrating adjacent structures. The primary objective of this project was to determine whether MGMT expression is associated with the invasiveness of PA. MATERIAL AND
METHOD: All patients who underwent surgical decompression consecutively between 2007-2012 were included. All data were obtained from the case records. Formalin-fixed paraffin-embedded (FFPE) tissue specimens were stained with hematoxylin and eosin (HE) and then examined via light microscope. Paraffin blocks that lacked necrosis and hemorrhage were chosen for histologic examination. In addition to an immunoprofile battery that consisted of Ki-67 and p53, MGMT, S-100 and Pan-CK were evaluated as well.
RESULTS: The subjects included 25 women and 15 men. The mean age was 48.9 ± 14.5 years. Of these, 63% of cases involved the invasion of adjacent structures. Of the PA, 17 (42%) were non-functioning pituitary adenomas (NFPA). There was a statistically significant relationship between the invasiveness and Ki-67, p53, MGMT expression, and prolactinoma. Gonodotropinomas were mostly non-invasive. FPAs presented invasive features more frequently than NFPAs. Pan-CK was positive in GH-secreting adenomas but negative in FSH- and LH-secreting adenomas.
CONCLUSION: Ki-67 and p53 in lower expression level can be used for evaluating invasiveness but not for recurrence. MGMT expression can be a useful IHC indicator for invasiveness. However, Pan-CK cannot be used for invasiveness or aggressiveness.

Entities:  

Keywords:  Ki-67; MGMT; cytokeratin; immunohistochemistry; invasiveness; p53; pituitary adenoma

Year:  2017        PMID: 31149189      PMCID: PMC6516582          DOI: 10.4183/aeb.2017.282

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  28 in total

Review 1.  MGMT: its role in cancer aetiology and cancer therapeutics.

Authors:  Stanton L Gerson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  Proliferation markers in different types of clinically non-secreting pituitary adenomas.

Authors:  S Schreiber; W Saeger; D K Lüdecke
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

Review 3.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.

Authors:  Bernd Kaina; Markus Christmann; Steffen Naumann; Wynand P Roos
Journal:  DNA Repair (Amst)       Date:  2007-05-07

4.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

Review 5.  Practical pituitary pathology: what does the pathologist need to know?

Authors:  Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

6.  Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

Authors:  Ann I McCormack; Kerrie L McDonald; Anthony J Gill; Susan J Clark; Morton G Burt; Kirsten A Campbell; Wilton J Braund; Nicholas S Little; Raymond J Cook; Ashley B Grossman; Bruce G Robinson; Roderick J Clifton-Bligh
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

7.  O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

Authors:  Georg Widhalm; Stefan Wolfsberger; Matthias Preusser; Adelheid Woehrer; Mark R Kotter; Thomas Czech; Christine Marosi; Engelbert Knosp
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

8.  Oncocytic transformation in pituitary adenomas: immunohistochemical analyses of 65 cases.

Authors:  María Niveiro; Francisco Ignacio Aranda; Artemio Payá; Evangelina Boix; Gloria Peiró; Antonio Picó
Journal:  Arch Pathol Lab Med       Date:  2004-07       Impact factor: 5.534

9.  MGMT immunohistochemical expression and promoter methylation in human glioblastoma.

Authors:  Fausto J Rodriguez; Stephen N Thibodeau; Robert B Jenkins; Karen V Schowalter; Bolette L Caron; Brian P O'neill; Charles David James; Charles David James; Sandra Passe; Jeff Slezak; Caterina Giannini
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-01

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.